Literature DB >> 14667622

Extraanatomic aortic bypass for repair of aortic arch coarctation via sternotomy: midterm clinical and magnetic resonance imaging results.

Sérgio Almeida de Oliveira1, Luiz Augusto F Lisboa, Luís Alberto O Dallan, Carlos Alberto C Abreu F, Carlos E Rochitte, Januário M de Souza.   

Abstract

BACKGROUND: We analyzed our 22 years of experience with extraanatomic bypass grafting for repair of aortic arch coarctation in adults. Results from early and midterm follow-up with clinical evaluation and magnetic resonance angiography are reported.
METHODS: Between November 1979 and December 2001, 18 consecutive patients aged 18 to 61 years (mean, 31.8 +/- 13.3 years) underwent extraanatomic bypass grafting to repair coarctation of the aortic arch. Six patients (33.3%) had recoarctation after previous repair through a left thoracotomy, and 3 (16.7%) had associated cardiac diseases. The operative technique used in all patients was ascending aorta-to-descending thoracic aorta bypass with a polyethylene terephthalate fiber (Dacron) graft through a median sternotomy and posterior pericardial approach.
RESULTS: Follow-up was completed in all patients, with a mean duration of 5.6 +/- 5.7 years (range, 12 months to 22 years). The follow-up interval exceeded 10 years in 5 patients. No neurologic complications, early or late mortality, late reoperations, or graft complications occurred. Six patients (33.3%) had mild hypertension. All patients were asymptomatic with patent Dacron grafts confirmed by echocardiography. Magnetic resonance angiography, performed in 15 (83.3%) patients, revealed that the Dacron grafts were still patent at a mean interval of 4.0 +/- 6.2 years (range, 5 days to 22 years) after repair.
CONCLUSIONS: Extraanatomic ascending aorta-to-descending thoracic aorta bypass grafting for repair of aortic arch coarctation in adults is safe, with low morbidity and no mortality. The favorable midterm results indicate this technique is a safe and less invasive means of repairing aortic arch coarctation or recoarctation in adults.

Entities:  

Mesh:

Year:  2003        PMID: 14667622     DOI: 10.1016/s0003-4975(03)01140-8

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

Review 1.  Role of surgery in the management of the adult patient with coarctation of the aorta.

Authors:  I Ramnarine
Journal:  Postgrad Med J       Date:  2005-04       Impact factor: 2.401

Review 2.  The Challenges of Redo Aortic Coarctation Repair in Adults.

Authors:  Jonathan D Price; Damien J LaPar
Journal:  Curr Cardiol Rep       Date:  2019-07-27       Impact factor: 2.931

3.  Ascending to Abdominal Aorta Extraanatomic Bypass for Descending Aortic Coarctation: A Reconstruction Technique without Laparotomy or Left Thoracotomy.

Authors:  Takafumi Terada; Takeshi Yuasa; Masahiko Hasegawa; Kazutaka Horiuchi; Shunsuke Nakata; Kenzo Yasuura
Journal:  Ann Vasc Dis       Date:  2014-09-25

Review 4.  Coarctation repair-redo challenges in the adults: what to do?

Authors:  Erik Beckmann; Arminder S Jassar
Journal:  J Vis Surg       Date:  2018-04-23

5.  Interruption of aortic arch in adults: surgical experience with extra-anatomic bypass.

Authors:  C Sai Krishna; Anil Bhan; Sanjeev Sharma; Usha Kiran; Panangipalli Venugopal
Journal:  Tex Heart Inst J       Date:  2005

6.  Coarctation of the aorta.

Authors:  R Prêtre
Journal:  HSR Proc Intensive Care Cardiovasc Anesth       Date:  2012

7.  Successful Ascending Aorta-Abdominal Aorta Bypass Graft through the Left Thoracic Cavity in a Patient with Atypical Coarctation.

Authors:  Shogo Obata; Shogo Mukai; Hironobu Morimoto; Toshifumi Hiraoka; Hiroaki Uchida; Yoshitaka Yamane
Journal:  Ann Vasc Dis       Date:  2013-08-30

8.  Single Stage Repair for Aortic Coarctation associated with Intracardiac Defects Using Extra-Anatomic Bypass Graft in Adults.

Authors:  Ibrahim Duvan; Mehmet Sanser Ates; Burak Emre Onuk; Beyhan Bakkaloglu; Umit Pinar Sungur; Murat Kurtoglu; Yahya Halidun Karagoz
Journal:  Korean Circ J       Date:  2016-07-21       Impact factor: 3.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.